Eli Lilly is facing $165 million in charges and development milestones from the U.S. Securities and Exchange Commission (SEC). The charges come from several in-process research and development projects acquired outside of a business combination.
U.S. Congress Proposes Bills to Strengthen Pharma Competition, Promote Innovation
Authorized Generics, Biosimilars, Branded Generics, Clinical Trials, Congress, Drug Price Reform, Drug Prices, Drug Pricing, Generic Substitution, Generics, House Committee on Oversight and Government Reform, Interchangeable Biosimilars, Pricing, R&D, R&D Investment ReturnOn Thursday, members of both the U.S. House of Representatives and the U.S. Senate introduced legislation that targets efforts that have limited competition, which keeps the price of prescription drugs high.
Boehringer Ingelheim Addresses Ukraine Crisis while Projecting 15 Launches by 2025
Blockbusters, Boehringer Ingelheim, Breakthrough Therapy Designation, Business, Eli Lilly, Fibrotic Diseases, Financials, Idiopathic Pulmonary Fibrosis (IPF), Launches, Pharma Companies, Product Launches, Product Pipeline, Product Pipelines, Product Pipelines, Quarterly results, R&D, R&D Investment Return, Russia invasion, SGLT2 Inhibitors, Therapeutics, UkraineBoehringer Ingelheim announced the company’s intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.